Efficacy of different regimens of steroid therapy in patients with exacerbation of chronic obstructive pulmonary disease
https://doi.org/10.18093/0869-0189-2015-25-1-58-63
Abstract
Exacerbation of chronic obstructive pulmonary disease (COPD) negatively influences on mortality, health-related quality of life and lung function decline. Systemic corticosteroids are used to treat acute exacerbations of COPD. Aim. This randomized parallel-group study was performed to evaluate short-term efficacy and safety of nebulized budesonide (n = 40) and budesonide via a dry powder inhaler (DPI) (n = 40) compared with intravenous (IV) prednisolone (n = 40) in patients with acute non-severe COPD exacerbations requiring hospitalization. Methods. The efficacy of treatment was assessed from the study entry to the Day 10. Clinical improvement was assessed according to an improvement in FEV1, FVC, FEV / FVC, Borg scale, 6-minute walking test (6-MWT), SGRQ-C and occurrence of adverse events. Results. Systemic prednisolone, budesonide DPI and nebulized budesonide improved lung function in patients with acute exacerbation of COPD. Inhaled corticosteroids did not demonstrate systemic activity compared to systemic prednisolone. Conclusion. Our study suggests that nebulized budesonide and high-dose budesonide DPI could be an alternative treatment to systemic steroids in patients with acute non-severe exacerbation of COPD.
About the Authors
P. Odonchimeg
The 3rd Central Clinical Hospital, 1, Ard Ayuush str., Ulan Bator, Mongolia;
Russian Federation
Russian Federation
PhD student, respiratory specialist, Pneumology Department, the 3rd Central Clinical Hospital; tel.: 976-998-557-89;
D. Ichinnorov
Mongolian National University of Medical Science, 3, S.Zorigiyn str., Ulan Bator, 210648, Mongolia
Russian Federation
Russian Federation
PhD, Assistant Professor of the Chair of Pneumology, Medical Faculty, Mongolian National University of Medical Science; tel.: 976-999-715-61;
Zh. Sarantuyaa
Mongolian National University of Medical Science, 3, S.Zorigiyn str., Ulan Bator, 210648, Mongolia
Russian Federation
Russian Federation
PhD, Head of Chair of Cell Biology and Genetics, Faculty of Pharmacia and Bionedicine, Mongolian National University of Medical Science, tel.: 976-990-927-71;
Ts. Tumur-Ochir
The 3rd Central Clinical Hospital, 1, Ard Ayuush str., Ulan Bator, Mongolia;
Russian Federation
Russian Federation
PhD, Head of the 3rd Central Clinical Hospital, consultant of Pneumology Department, tel.: 976-990-372-27;
G. Choyzhamts
Mongolian National University of Medical Science, 3, S.Zorigiyn str., Ulan Bator, 210648, Mongolia
Russian Federation
Russian Federation
PhD, Professor of Chair of Clinical Pharmacology, Faculty of Pharmacia and Bionedicine, Mongolian National University of Medical Science, tel.: 976-991-142-53,
References
1. Global Strategy for the Diagnosis, Management, and Prevention of COPD. Scientific information and recommendations for COPD programs. Updated 2013. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013Feb13.pdf
2. Soler-Cataluna J.J., Martinez-Garcia M.A., Roman S.P. et al. Severe acute exacerbations and mortality in patients with COPD. Thorax. 2005; 60: 925–931.
3. Maltais F., Ostinelli J., Bourbeau J. et al. Comparison of nebulized budesonide and oral predisolone with placebo in the treatment of acute exacerbations of COPD: a randomized controlled trial. Am. J. Respir. Crit. Care Med. 2002, 165: 698–703.
4. Gunen H., Hacievliyagil S.S., Yetkin O. The role of nebilized budesonide in the treatment of exacerbations of COPD. Eur. Respir. J. 2007, 29: 660–667.
5. Henzen C., Suter A., Lerch E. et al. Supression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet. 2000; 355: 542–545.
6. Burge P.S., Calverley P.M., Jones P.W. et al. Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe COPD: the ISOLDE trial. Br. Med. J. 2000, 320: 1297–1303.
7. Szafranski W., Cukier A., Ramirez A. et al. Efficacy and safety of budesonide and formoterol in the management of COPD. Eur. Respir. J. 2003; 21: 74–81.
8. Calverley P.M., Boonsawat W., Cseke Z. et al. Maintenance therapy with budesonide and formoterol in COPD. Eur. Resir. J. 2003, 22: 912–919.
9. Calverley P.M., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the treatment of COPD:a randomized controlled trial. Lancet 2003, 361 (9356): 449–456.
10. Calverley P.M., Anderson J.A., Celli B. et al. TORCH investigators. Salmeterol and fluticasone protionate and survival in COPD. N. Engl. J. Med. 2007, 356: 775–789.
11. Borg G. Psychophysical bases of perceived exertion. Med. Sci. Sports Exer. 1982; 14: 377–381.
12. Niewoehner D.E., Erbland M.L., Deupree R.H. et al. Effect of systemic glucocorticoids on exacerbations of Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. 1999; 340: 1941–1947.
13. Davies L., Angus R.M., Calverley P.M.A. Oral corticosteroids in patients admitted to hospital with exacerbations of Chronic Obstructive Pulmonary Disease: a prospective randomized controlled trial. Lancet. 1999; 354: 456–460.
14. Albert R.K., Martin T.R., Lewis S.W. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory failure. Ann. Intern. Med. 1980; 92: 753–758.
15. Maltais F., Ostinelli J., Bourbeau J. et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A randomized controlled trial. Am. J. Respir. Crit. Care Med. 2002; 165: 698–703.
16. Jones PW, Quirk FH, Baveystock CM. The St. George’s Respiratory Questionnaire. Respir Med 1991; 85:25-31.
17. Falk J.A., Minai O.A., Mosenifar Z. Inhaled and systemic corticosteroids in Chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2008; 5: 506–512.
18. Seemungal T.A.R., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with COPD. Am. J. Respir. Crit. Care Med. 1998; 151: 1418–1422.
19. Zielinski J., MacNee W., Wedzicha J. et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch. Chest Dis. 1997; 52: 43–47.
20. Donaldson G.C., Seemungal T.A.R., Browmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in COPD. Thorax. 2002; 57: 847–852.
21. Seemungal T.A., Donaldson G.C., Browmik A. et al. Time course and recovery of exacerbations in patients with COPD. Am. J. Respir. Crit. Care Med. 2000; 161: 1608–1613.
22. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbation. Chest. 2000; 117: 398–401.
23. Burge S.Wedzicha J.A. COPD exacerbations: definitions and classifications. Eur. Respir. J. Suppl. 2003; 41: 46S–53S.
24. Celli B.R., Barnes P.J. Exacerbations of COPD. Eur. Respir. J. 2007; 29: 1224–1238.
25. Чучалин А.Г. Стандарты диагностики и лечения ХОБЛ. М.: Атмосфера; 2010.
26. Авдеев С.Н. Карманное руководство для практических врачей. М.: Атмосфера; 2010.
Review
For citations:
Odonchimeg P., Ichinnorov D., Sarantuyaa Zh., Tumur-Ochir Ts., Choyzhamts G. Efficacy of different regimens of steroid therapy in patients with exacerbation of chronic obstructive pulmonary disease. PULMONOLOGIYA. 2015;25(1):58-63. (In Russ.) https://doi.org/10.18093/0869-0189-2015-25-1-58-63
Views:
4270
Email this article 